The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

Sep. 08, 2020
Applicant:

Japanese Foundation for Cancer Research, Tokyo, JP;

Inventors:

Ryohei Katayama, Tokyo, JP;

Ken Uchibori, Tokyo, JP;

Naoya Fujita, Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/662 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2018.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/662 (2013.01); A61P 35/00 (2018.01); C12Q 1/68 (2013.01); G01N 33/574 (2013.01); A61K 45/06 (2013.01);
Abstract

A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.


Find Patent Forward Citations

Loading…